Richard O. Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard O. Chen has a total of 400 co-authors. Here are the top co-authors by number of shared publications:
- Christopher R. Cabanski
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
26 shared publications - Diani Fernanda da Silva Less
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
25 shared publications - Theresa LaVallee
Parker Institute for Cancer Immunotherapy, San Francisco, California
25 shared publications - Jill O’DOnnell-Tormey
12Cancer Research Institute, New York, New York
24 shared publications - Justin Fairchild
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
24 shared publications - Marko Spasic
Parker Institute for Cancer Immunotherapy, San Francisco, California
24 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
- 8 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessOlaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S1 shows the representativeness of participants enrolled in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S1 shows the representativeness of participants enrolled in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S8 shows the biopsy location and specimen type for tumor biopsy samples used for RNA-seq analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S8 shows the biopsy location and specimen type for tumor biopsy samples used for RNA-seq analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S4 summarizes exposure to the study drugs in Cohort B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S4 summarizes exposure to the study drugs in Cohort B.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S9 shows pathways that are differentially expressed pre-treatment between patients who achieved disease control and those who did not from gene set enrichment analysis of RNA-Seq data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S9 shows pathways that are differentially expressed pre-treatment between patients who achieved disease control and those who did not from gene set enrichment analysis of RNA-Seq data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S3 summarizes exposure to the study drugs in Cohort A.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S3 summarizes exposure to the study drugs in Cohort A.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Figure S1 shows the gating strategy for mass cytometry (CyTOF).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Figure S1 shows the gating strategy for mass cytometry (CyTOF).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S6 lists demographics, baseline disease characteristics, and outcomes for patients who achieved disease control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Table S6 lists demographics, baseline disease characteristics, and outcomes for patients who achieved disease control.